Tokai Pharmaceuticals : Announces Presentation of Galeterone Data in Models of the AR-V7 Splice Variant at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

… and commercializing innovative therapies for prostate cancer and other hormonally driven diseases … with treatment-naïve metastatic castration-resistant prostate cancer (mCRPC) whose prostate tumors have C-terminal loss—the …